Browse > Article
http://dx.doi.org/10.5483/BMBRep.2021.54.11.101

Drug evaluation based on phosphomimetic PDHA1 reveals the complexity of activity-related cell death in A549 non-small cell lung cancer cells  

Jin, Ling (Department of Korean Medical Science, School of Korean Medicine, Pusan National University)
Cho, Minkyoung (Korean Medical Research Center for Healthy Aging, Pusan National University)
Kim, Bo-Sung (Department of Korean Medical Science, School of Korean Medicine, Pusan National University)
Han, Jung Ho (Department of Korean Medical Science, School of Korean Medicine, Pusan National University)
Park, Sungmi (Department of Internal Medicine, School of Medicine, Kyungpook National University)
Lee, In-Kyu (Department of Internal Medicine, School of Medicine, Kyungpook National University)
Ryu, Dongryeol (Department of Molecular Cell Biology, School of Medicine, Sungkyunkwan University)
Kim, Jae Ho (Department of Physiology, College of Medicine, Pusan National University)
Bae, Sung-Jin (Korean Medical Research Center for Healthy Aging, Pusan National University)
Ha, Ki-Tae (Department of Korean Medical Science, School of Korean Medicine, Pusan National University)
Publication Information
BMB Reports / v.54, no.11, 2021 , pp. 563-568 More about this Journal
Abstract
Cancer cells predominantly generate energy via glycolysis, even in the presence of oxygen, to support abnormal cell proliferation. Suppression of PDHA1 by PDK1 prevents the conversion of cytoplasmic pyruvate into Acetyl-CoA. Several PDK inhibitors have been identified, but their clinical applications have not been successful for unclear reasons. In this study, endogenous PDHA1 in A549 cells was silenced by the CRISPR/Cas9 system, and PDHA1WT and PDHA13SD were transduced. Since PDHA13SD cannot be phosphorylated by PDKs, it was used to evaluate the specific activity of PDK inhibitors. This study highlights that PDHA1WT and PDHA13SD A549 cells can be used as a cell-based PDK inhibitor-distinction system to examine the relationship between PDH activity and cell death by established PDK inhibitors. Leelamine, huzhangoside A and otobaphenol induced PDH activity-dependent apoptosis, whereas AZD7545, VER-246608 and DCA effectively enhanced PDHA1 activity but little toxic to cancer cells. Furthermore, the activity of phosphomimetic PDHA1 revealed the complexity of its regulation, which requires further in-depth investigation.
Keywords
Apoptosis; Glycolysis; PDHA1; PDK; Warburg effect;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Mayers R, Butlin R, Kilgour E et al (2003) AZD7545, a novel inhibitor of pyruvate dehydrogenase kinase 2 (PDHK2), activates pyruvate dehydrogenase in vivo and improves blood glucose control in obese (fa/fa) Zucker rats. Biochem Soc Trans 31, 1165-1167   DOI
2 Kolobova E, Tuganova A, Boulatnikov I and Popov KM (2001) Regulation of pyruvate dehydrogenase activity through phosphorylation at multiple sites. Biochem J 358, 69-77   DOI
3 Liu T and Yin H (2017) PDK1 promotes tumor cell proliferation and migration by enhancing the Warburg effect in non-small cell lung cancer. Oncol Rep 37, 193-200   DOI
4 Cai Z, Li CF, Han F et al (2020) Phosphorylation of PDHA by AMPK drives TCA cycle to promote cancer metastasis. Mol Cell 80, 263-278. e267   DOI
5 Korotchkina LG and Patel MS (2001) Site specificity of four pyruvate dehydrogenase kinase isoenzymes toward the three phosphorylation sites of human pyruvate dehydrogenase. J Biol Chem 276, 37223-37229   DOI
6 Jeoung NH (2015) Pyruvate dehydrogenase kinases: therapeutic targets for diabetes and cancers. Diabetes Metab J 39, 188-197   DOI
7 Kato M, Li J, Chuang JL and Chuang DT (2007) Distinct structural mechanisms for inhibition of pyruvate dehydrogenase kinase isoforms by AZD7545, dichloroacetate, and radicicol. Structure 15, 992-1004   DOI
8 Sun W, Xie Z, Liu Y et al (2015) JX06 selectively inhibits pyruvate dehydrogenase kinase PDK1 by a covalent cysteine modification. Cancer Res 75, 4923-4936   DOI
9 Moore JD, Staniszewska A, Shaw T et al (2014) VER-246608, a novel pan-isoform ATP competitive inhibitor of pyruvate dehydrogenase kinase, disrupts Warburg metabolism and induces context-dependent cytostasis in cancer cells. Oncotarget 5, 12862   DOI
10 Zimmer AD, Walbrecq G, Kozar I, Behrmann I and Haan C (2016) Phosphorylation of the pyruvate dehydrogenase complex precedes HIF-1-mediated effects and pyruvate dehydrogenase kinase 1 upregulation during the first hours of hypoxic treatment in hepatocellular carcinoma cells. Hypoxia 4, 135   DOI
11 SALE GJ and Randle PJ (1981) Analysis of site occupancies in [32P] phosphorylated pyruvate dehydrogenase complexes by aspartyl-prolyl cleavage of tryptic phosphopeptides. Eur J Biochem 120, 535-540   DOI
12 Golias T, Papandreou I, Sun R et al (2016) Hypoxic repression of pyruvate dehydrogenase activity is necessary for metabolic reprogramming and growth of model tumours. Sci Rep 6, 1-11   DOI
13 Guerra-Castellano A, Diaz-Moreno I, Velazquez-Campoy A, Miguel A and Diaz-Quintana A (2016) Structural and functional characterization of phosphor-mimetic mutants of cytochrome c at threonine 28 and serine 47. Biochim Biophys Acta-Bioenerg 1857, 387-395   DOI
14 Zheng J (2012) Energy metabolism of cancer: glycolysis versus oxidative phosphorylation. Oncol Lett 4, 1151-1157   DOI
15 Vander Heiden MG, Cantley LC and Thompson CB (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324, 1029-1033   DOI
16 Kroemer G and Pouyssegur J (2008) Tumor cell metabolism: Cancer's Achilles' heel. Cancer Cell 13, 472-482   DOI
17 Gatenby RA and Gillies RJ (2004) Why do cancers have high aerobic glycolysis? Nat Rev Cancer 4, 891-899   DOI
18 Pelicano H, Martin D, Xu R, and and Huang P (2006) Glycolysis inhibition for anticancer treatment. Oncogene 25, 4633   DOI
19 Jeoung NH (2015) Pyruvate dehydrogenase kinases: therapeutic targets for diabetes and cancers. Diabetes Metab J 39, 188   DOI
20 McFate T, Mohyeldin A, Lu H et al (2008) Pyruvate dehydrogenase complex activity controls metabolic and malignant phenotype in cancer cells. J Biol Chem 283, 22700-22708   DOI
21 Kato M, Wynn RM, Chuang JL et al (2008) Structural basis for inactivation of the human pyruvate dehydrogenase complex by phosphorylation: role of disordered phosphorylation loops. Structure 16, 1849-1859   DOI
22 Sradhanjali S and Reddy MM (2018) Inhibition of pyruvate dehydrogenase kinase as a therapeutic strategy against cancer. Curr Top Med Chem 18, 444-453   DOI
23 Korotchkina LG and Patel MS (1995) Mutagenesis studies of the phosphorylation sites of recombinant human pyruvate dehydrogenase. Site-specific regulation. J Biol Chem 270, 14297-14304   DOI
24 Jing E, O'Neill BT, Rardin MJ et al (2013) Sirt3 regulates metabolic flexibility of skeletal muscle through reversible enzymatic deacetylation. Diabetes 62, 3404-3417   DOI
25 Kwak CH, Jin L, Han JH et al (2020) Ilimaquinone induces the apoptotic cell death of cancer cells by reducing pyruvate dehydrogenase kinase 1 activity. Int J Mol Sci 21, 6021   DOI
26 Schell JC, Olson KA, Jiang L et al (2014) A role for the mitochondrial pyruvate carrier as a repressor of the Warburg effect and colon cancer cell growth. Mol Cell 56, 400-413   DOI
27 Li J, Kato M and Chuang DT (2009) Pivotal role of the C-terminal DW-motif in mediating inhibition of pyruvate dehydrogenase kinase 2 by dichloroacetate. J Biol Chem 284, 34458-34467   DOI
28 Sun W, Xie Z, Liu Y et al (2015) JX06 selectively inhibits pyruvate dehydrogenase kinase PDK1 by a covalent cysteine modification. Cancer Res 75, 4923-4936   DOI
29 Jeoung NH and Harris RA (2010) Role of pyruvate dehydrogenase kinase 4 in regulation of blood glucose levels. Diabetes Metab J 34, 274
30 Kwak CH, Lee JH, Kim EY et al (2019) Huzhangoside A suppresses tumor growth through inhibition of pyruvate dehydrogenase kinase activity. Cancers 11, 712   DOI
31 Jin L, Kim EY, Chung T-W et al (2020) Hemistepsin A suppresses colorectal cancer growth through inhibiting pyruvate dehydrogenase kinase activity. Sci Rep 10, 1-12   DOI
32 Hitosugi T, Fan J, Chung TW et al (2011) Tyrosine phosphorylation of mitochondrial pyruvate dehydrogenase kinase 1 is important for cancer metabolism. Mol Cell 44, 864-877   DOI
33 Wang X, Shen X, Yan Y and Li H (2021) Pyruvate dehydrogenase kinases (PDKs): an overview toward clinical applications. Biosci Rep 41, BSR20204402   DOI
34 Stacpoole PW (2017) Therapeutic targeting of the pyruvate dehydrogenase complex/pyruvate dehydrogenase kinase (PDC/PDK) axis in cancer. JNCI: J Natl Cancer Inst 109, 11   DOI